



Regulation of Fibronectin and Collagen Type I, III and VI by TNF- α , TGF- β , IL-13, and Tofacitinib in Dermal Fibroblasts


Supplementary data



Supplementary figure 1. TGF- β 1, TNF- α , IL-4 and IL-13 dose dependently increase collagen and fibronectin formation. Graphs depict four-parameter logistic regression performed on the area under curve (AUC) values of individual technical replicates following for twelve days stimulation. Error within donors represents SD from four technical replicates. EC50 values is listed in the bottom-right corner of individual graphs, based on the mean regression of four biological replicates. A) The effect of increasing doses of TGF- β 1 on the formation of type I, III, VI collagen and fibronectin. B) The effect of increasing doses of TNF- α on the formation of type I, III, VI collagen and fibronectin. C) The effect of increasing doses of IL-4 on the formation of type I, III, VI collagen and fibronectin. D) The effect of increasing doses of IL-13 on the formation of type I, III, VI collagen and fibronectin.



Supplementary figure 2. The effect of tofacitinib on collagen and fibronectin formation over twelve days of stimulation with IL-13 and/or TGF- β 1. Tofacitinib was included from day four of culture in parallel treatments. A) type I collagen formation measured by the PRO-C1 assay. B) Type III collagen formation measured by the PRO-C3 assay. C) Type VI collagen formation measured by the PRO-C6 assay. D) Fibronectin formation measured by the FBN-C assay. Asterisks (*) depict a significant difference compared to vehicle, color coded according to treatment. Fibroblasts treated with IL-13 + TGF- β 1 were tested for significance against TGF- β 1 alone. Crosses (+) are color coded and denote a significant contrast of tofacitinib compared to the parallel treatment without tofacitinib.



Supplementary figure 3. The effect of tofacitinib on collagen and fibronectin formation over twelve days of stimulation with TNF- α and/or TGF- β 1. Tofacitinib was included from day four of culture in parallel treatments. A) type I collagen formation measured by the PRO-C1 assay. B) Type III collagen formation measured by the PRO-C3 assay. C) Type VI collagen formation measured by the PRO-C6 assay. D) Fibronectin formation measured by the FBN-C assay. Asterisks (*) depict a significant difference compared to vehicle, color coded according to treatment. Fibroblasts treated with IL-13 + TGF- β 1 were tested for significance against TGF- β 1 alone. Crosses (+) are color coded and denote a significant contrast of tofacitinib compared to the parallel treatment without tofacitinib.